CN104470542A - 用于稳定和长期植入的联合疗法 - Google Patents

用于稳定和长期植入的联合疗法 Download PDF

Info

Publication number
CN104470542A
CN104470542A CN201280068202.9A CN201280068202A CN104470542A CN 104470542 A CN104470542 A CN 104470542A CN 201280068202 A CN201280068202 A CN 201280068202A CN 104470542 A CN104470542 A CN 104470542A
Authority
CN
China
Prior art keywords
cell
subject
cells
antibody
depleted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280068202.9A
Other languages
English (en)
Chinese (zh)
Inventor
雅尔·赖斯纳
埃斯特·巴沙尔勒斯蒂格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN104470542A publication Critical patent/CN104470542A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
CN201280068202.9A 2011-12-22 2012-12-20 用于稳定和长期植入的联合疗法 Pending CN104470542A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578917P 2011-12-22 2011-12-22
US61/578,917 2011-12-22
PCT/IL2012/050542 WO2013093920A2 (en) 2011-12-22 2012-12-20 A combination therapy for a stable and long term engraftment

Publications (1)

Publication Number Publication Date
CN104470542A true CN104470542A (zh) 2015-03-25

Family

ID=48669650

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280068202.9A Pending CN104470542A (zh) 2011-12-22 2012-12-20 用于稳定和长期植入的联合疗法
CN201280068917.4A Pending CN104093314A (zh) 2011-12-22 2012-12-20 使用针对t/b细胞耗尽的特异性方案的用于稳定和长期植入的联合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280068917.4A Pending CN104093314A (zh) 2011-12-22 2012-12-20 使用针对t/b细胞耗尽的特异性方案的用于稳定和长期植入的联合疗法

Country Status (16)

Country Link
US (5) US10369172B2 (https=)
EP (2) EP2793914B1 (https=)
JP (3) JP2015504047A (https=)
KR (2) KR102109643B1 (https=)
CN (2) CN104470542A (https=)
AU (3) AU2012355989B2 (https=)
BR (2) BR112014015959A8 (https=)
CA (2) CA2859953A1 (https=)
DK (2) DK2797421T3 (https=)
ES (2) ES2811529T3 (https=)
IN (2) IN2014MN01467A (https=)
MX (2) MX370404B (https=)
RU (2) RU2648354C2 (https=)
SG (3) SG11201403459XA (https=)
WO (2) WO2013093920A2 (https=)
ZA (2) ZA201405071B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108025026A (zh) * 2015-07-16 2018-05-11 耶达研究及发展有限公司 抗第三方中央型记忆t细胞的用途
CN108473949A (zh) * 2015-12-04 2018-08-31 弗莱德哈钦森癌症研究中心 扩增的造血干细胞/祖细胞群体的用途
CN109562127A (zh) * 2016-06-03 2019-04-02 纪念斯隆-凯特琳癌症中心 作为早期治疗选择的过继细胞疗法
CN112669992A (zh) * 2020-12-30 2021-04-16 中国人民解放军总医院 单倍体造血干细胞移植atg个体化用药量的计算方法
CN112930187A (zh) * 2018-09-27 2021-06-08 弗斯弗加姆股份有限公司 用于同种异体γ/δ-T细胞的扩增和使用的方法和组合物
US11324777B2 (en) 2011-09-08 2022-05-10 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
CN115137752A (zh) * 2015-08-25 2022-10-04 Uab研究基金会 用于干细胞移植的方法
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140102730A (ko) 2011-12-08 2014-08-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 포유류 태아 폐 세포와 이를 치료용으로 사용하는 방법
MX370404B (es) 2011-12-22 2019-12-11 Yeda Res & Dev Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
AU2014262532B2 (en) 2013-05-09 2019-08-22 Advanced Neuroregenerative Therapies, Llc G-CSF for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal
ES2917884T3 (es) 2015-06-18 2022-07-12 Yeda Res & Dev Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos
WO2017203520A1 (en) 2016-05-22 2017-11-30 Yeda Research And Development Co. Ltd. Methods of using pulmonary cells for transplantation and induction of tolerance
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
MX395639B (es) 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
EP3595683A1 (en) 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
MX2020004811A (es) * 2017-11-15 2020-10-07 Weird Science Llc Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
DK3749334T3 (da) 2018-02-08 2025-02-17 Univ Leland Stanford Junior Allogen hæmatopoietisk stamcelletransplantation
WO2019178106A1 (en) * 2018-03-12 2019-09-19 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
WO2020061180A1 (en) * 2018-09-18 2020-03-26 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
EP3873502A4 (en) * 2018-11-01 2022-06-29 Children's Hospital Medical Center Reduced intensity conditioning with melphalan
CN109781987B (zh) * 2019-01-09 2022-04-26 暨南大学 终末效应t细胞亚群在制备辅助评估再生障碍性贫血病情程度试剂盒中的应用
EP3953383A4 (en) * 2019-04-08 2023-01-18 Russell Biotech, Inc. Improved manufacturing procedures for cell based therapies
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
RU2723164C1 (ru) * 2019-10-07 2020-06-09 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ расчета дозы клеток-предшественниц гемопоэза в лейкоцитаферезном продукте путем учета изменения целостности клеточных мембран при хранении
JP2023500277A (ja) * 2019-11-05 2023-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｔ細胞媒介性自己免疫疾患の治療におけるベト細胞の使用
EP4157989A4 (en) * 2020-05-28 2024-06-26 Biomagnetic Solutions LLC COMPOSITIONS AND METHODS FOR NEGATIVE SELECTION OF NATIVE T AND B CELLS WITH A SINGLE ANTIBODY
CN117279650A (zh) * 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
RU2764742C1 (ru) * 2021-04-09 2022-01-20 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТИО им. академика В.И. Шумакова" Минздрава России) Способ подбора режима иммуносупрессии детям раннего возраста в отдаленном периоде после трансплантации печени
US20250114360A1 (en) * 2022-02-03 2025-04-10 The Regents Of The University Of California Novel regimen for augmenting and extending transplant tolerance
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5806529A (en) * 1993-11-03 1998-09-15 Yeda Research And Development Co. Ltd. Bone marrow transplantation
US5928639A (en) * 1994-03-17 1999-07-27 Hadasit Medical Research Services And Development Ltd. Immunotherapy of cancer with allogeneic lymphocytes
US6491917B1 (en) * 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients
US6544787B1 (en) * 1996-11-15 2003-04-08 Hadash Medical Research Services And Development Ltd. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
US20040185043A1 (en) * 2001-05-09 2004-09-23 Ildstad Suzanne T. Hematopoietic stem cell chimerism to treat autoimmune disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20010009663A1 (en) * 1993-09-13 2001-07-26 Suzanne T. Ildstad Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6217867B1 (en) 1993-09-13 2001-04-17 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5514364A (en) 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6039684A (en) 1997-12-11 2000-03-21 Allegheny University Of The Health Sciences Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
US6558662B2 (en) * 1997-11-14 2003-05-06 The General Hospital Corporation Treatment of hematologic disorders
AU2003204277B2 (en) 1997-11-14 2006-03-16 The General Hospital Corporation Treatment of hematologic disorders
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
WO2002040050A1 (en) 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
AU2002239424A1 (en) 2000-11-14 2002-05-27 The University Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients
WO2002040640A2 (en) 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
US20050118142A1 (en) 2001-08-01 2005-06-02 Ildstad Suzanne T. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US20070141027A1 (en) 2003-05-28 2007-06-21 University Of Louisville Research Foundation Inc. Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation
WO2005023982A2 (en) 2003-05-28 2005-03-17 Univ. Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
DE102009040716B4 (de) * 2009-09-10 2011-07-14 Miltenyi Biotec GmbH, 51429 Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen
MX370404B (es) 2011-12-22 2019-12-11 Yeda Res & Dev Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
US20210045900A1 (en) 2019-08-13 2021-02-18 Stryker Corporation Stent braid pattern with enhanced radiopacity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5806529A (en) * 1993-11-03 1998-09-15 Yeda Research And Development Co. Ltd. Bone marrow transplantation
US5928639A (en) * 1994-03-17 1999-07-27 Hadasit Medical Research Services And Development Ltd. Immunotherapy of cancer with allogeneic lymphocytes
US6544787B1 (en) * 1996-11-15 2003-04-08 Hadash Medical Research Services And Development Ltd. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
US6491917B1 (en) * 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients
US20040185043A1 (en) * 2001-05-09 2004-09-23 Ildstad Suzanne T. Hematopoietic stem cell chimerism to treat autoimmune disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOSEFINA H. DYKES等: "Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults", 《TRANSFUSION》 *
LEO LUZNIK等: "HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide", 《BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324777B2 (en) 2011-09-08 2022-05-10 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
US12133866B2 (en) 2011-09-08 2024-11-05 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US11844827B2 (en) 2015-07-16 2023-12-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
US11179448B2 (en) 2015-07-16 2021-11-23 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
CN108025026A (zh) * 2015-07-16 2018-05-11 耶达研究及发展有限公司 抗第三方中央型记忆t细胞的用途
US12508307B2 (en) 2015-07-16 2025-12-30 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
CN115137752A (zh) * 2015-08-25 2022-10-04 Uab研究基金会 用于干细胞移植的方法
CN108473949A (zh) * 2015-12-04 2018-08-31 弗莱德哈钦森癌症研究中心 扩增的造血干细胞/祖细胞群体的用途
CN109562127A (zh) * 2016-06-03 2019-04-02 纪念斯隆-凯特琳癌症中心 作为早期治疗选择的过继细胞疗法
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
CN112930187A (zh) * 2018-09-27 2021-06-08 弗斯弗加姆股份有限公司 用于同种异体γ/δ-T细胞的扩增和使用的方法和组合物
CN112669992A (zh) * 2020-12-30 2021-04-16 中国人民解放军总医院 单倍体造血干细胞移植atg个体化用药量的计算方法
CN112669992B (zh) * 2020-12-30 2024-06-11 中国人民解放军总医院 单倍体造血干细胞移植atg个体化用药量的计算方法

Also Published As

Publication number Publication date
SG11201403459XA (en) 2014-07-30
JP2018080201A (ja) 2018-05-24
US20140369974A1 (en) 2014-12-18
ES2864323T3 (es) 2021-10-13
BR112014015959A8 (pt) 2017-07-04
KR20140107564A (ko) 2014-09-04
CA2859952C (en) 2023-04-04
SG10201801905WA (en) 2018-04-27
IN2014MN01468A (https=) 2015-05-01
MX2014007647A (es) 2015-04-13
BR112014015960A2 (pt) 2017-06-13
JP2015504047A (ja) 2015-02-05
US20190328793A1 (en) 2019-10-31
WO2013093920A8 (en) 2013-09-12
ZA201405298B (en) 2015-11-25
KR102109643B1 (ko) 2020-05-29
BR112014015959A2 (pt) 2017-06-13
JP2015502401A (ja) 2015-01-22
EP2797421B1 (en) 2020-05-20
AU2012355990A1 (en) 2014-07-31
EP2793914A4 (en) 2016-02-10
US11497776B2 (en) 2022-11-15
RU2014129632A (ru) 2016-02-10
MX2014007648A (es) 2015-03-19
US11504399B2 (en) 2022-11-22
MX370404B (es) 2019-12-11
HK1202775A1 (en) 2015-10-09
US10369172B2 (en) 2019-08-06
CA2859953A1 (en) 2013-06-27
US10434121B2 (en) 2019-10-08
EP2793914B1 (en) 2021-02-03
BR112014015960A8 (pt) 2017-07-04
JP6313219B2 (ja) 2018-04-18
SG11201403456UA (en) 2014-07-30
WO2013093919A3 (en) 2013-10-10
IN2014MN01467A (https=) 2015-05-01
CA2859952A1 (en) 2013-06-27
AU2016259415B2 (en) 2018-04-26
WO2013093920A2 (en) 2013-06-27
US20190358269A1 (en) 2019-11-28
EP2797421A2 (en) 2014-11-05
HK1202810A1 (en) 2015-10-09
RU2014128479A (ru) 2016-02-10
WO2013093919A2 (en) 2013-06-27
KR20140105848A (ko) 2014-09-02
DK2793914T3 (da) 2021-04-26
WO2013093920A3 (en) 2014-11-27
AU2016259415A1 (en) 2016-12-08
RU2657758C2 (ru) 2018-06-15
AU2012355989A1 (en) 2014-08-07
US20140363437A1 (en) 2014-12-11
AU2012355989B2 (en) 2016-12-15
CN104093314A (zh) 2014-10-08
ES2811529T3 (es) 2021-03-12
ZA201405071B (en) 2015-11-25
AU2012355990B2 (en) 2017-10-12
RU2648354C2 (ru) 2018-03-23
EP2793914A2 (en) 2014-10-29
US20230039904A1 (en) 2023-02-09
DK2797421T3 (da) 2020-08-24
WO2013093919A8 (en) 2013-08-22
EP2797421A4 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
US20230039904A1 (en) Combination therapy for a stable and long term engraftment
EP2297306B1 (en) Human facilitating cells
Kapoor et al. Hematopoietic stem cell transplantation for primary immune deficiency disorders
NZ627272B2 (en) A combination therapy for a stable and long term engraftment
NZ627272A (en) A combination therapy for a stable and long term engraftment
Gaballa et al. Hematopoietic stem cell transplantation
HK1202810B (en) A combination therapy for a stable and long term engraftment
Rezvani et al. Introduction to hematopoietic cell transplantation
Kohrt Strategies to Enhance Anti-Tumor Immunity: Translating Preclinical Models
Ilhan et al. Incidence of graft vs host disease in allogeneic bone marrow transplantation in a single center study from Turkey
Houtchens et al. A high throughput SNP based KIR genotyping system for use in allogeneic transplantation and outcomes analyses
Gatti et al. History of hematopoietic stem cell transplantation
Alam et al. Transplantation of Haematopoietic Stem Cells
Buhmann et al. Publication only EBMT 2008
HK1202775B (en) A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150325